Charles River Laboratories International

Charles River Laboratories International, Inc. (NYSE: CRL) is a leading provider of essential products and services to accelerate drug discovery and development for pharmaceutical and biotechnology companies, government agencies, and academic institutions.

The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. RMS provides research models, associated services, and research model services including insourcing solutions. DSA offers a suite of drug discovery and safety assessment services. Manufacturing Solutions provides microbial solutions, biologics testing solutions, and avian vaccine services.

Charles River's key services include:

• Research models and associated services

• Discovery services

• Safety assessment

• Biologics testing solutions

• Microbial solutions

• Contract development and manufacturing organization (CDMO) services

In recent developments, Charles River launched a real-time research model ordering system in October 2023 to digitize its inventory and provide a seamless online ordering experience. The company is implementing restructuring initiatives expected to result in over USD 150 million in annualized cost savings by the third quarter of 2024. Charles River's Board approved a new USD 1 billion stock repurchase authorization in August 2024.